Lupin obtains USFDA EIR for unit 3 of the Pithampur facility
Date: 2018-12-12   Author: Sunil Hebbalkar  Category: #news

Lupin obtains USFDA EIR for unit 3 of the Pithampur facility

Lupin Limited, a transnational pharmaceutical company based in Mumbai, has reportedly received an Establishment Inspection Report (EIR) from the U.S. regulator for the unit 3 of the facility in Madhya Pradesh.

As per sources familiar with the knowledge of the matter, the unit 3 of Pithampur facility was inspected from June 12 till June 16, in the year 2017. Lupin also mentioned in a BSE filing that this was a pre-approval inspection of a product known as Albuterol Sulfate Inhalation.

Nilesh Gupta, Managing Director, Lupin Limited, said that receiving the Establishment Inspection Report (EIR) for the Pithampur unit 3 facility is a rather motivating development. He also added that this is indeed a proof of their commitment to maintain the highest standards in compliance and quality across their facilities.

For the record, the U.S. Food and Drug Administration (USFDA) issues an Establishment Inspection Report (EIR) to the facility that is the subject of a USFDA or inspection by an FDA-contracted agency when they decide to close the inspection. Establishment Inspection Report (EIR) is the term given by the U.S. Food and Drug Administration (USFDA) for the whole narration of what the FDA investigator or inspector did throughout the time spent in the establishment (i.e. a facility), from the period of introduction till the delivery of the inspectional observations.

Incidentally, the week before Lupin announced the completion of USFDA inspections at its Mandideep location that plays host to the company's Cephalosporin Solid Oral Dosage Form facility, and Cephalosporin and Cardiovascular Pril API facilities. The inspections took place from November 26 till December 4, 2018.

Ironically, despite receiving the EIR from the FDA, Lupin’s stock was trading at Rs 824.15 on BSE, down 1.88 percent from its previous close.

For the record, the company manufactures dry powder inhalers, dermatological products, and metered dose inhalers.



About Author


Sunil Hebbalkar

Sunil Hebbalkar

Sunil currently works as an content writer at AlgosOnline. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Foll...

Read More

More from Sunil


Post Recommendents

SoftBank to lead funding round of USD 100 million in Snapdeal
Author: Paroma Bhattacharya

  • Japanese multinational company to lead $100 million funding round for the Indian online firm Snapdeal.
     
  • Kunal Bahl presented an ide...


Indian robotics startup Miko secures $7.5 million in Series A funding
Author: Saipriya Iyer

The investment will be used to expand Miko’s market in the UK, North America and West Asia as well as to develop a new line of products.

Miko, an Indian sta...


OSF Ventures participates in $35M funding round for Exo Imaging
Author: Sunil Hebbalkar

OSF Ventures, part of the renowned OSF HealthCare family, has recently joined a funding round worth $35M for Redwood-based start-up Exo Imaging to help it attain FDA approval. The funding is also targeted toward develo...